GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Second Sight Medical Products Inc (NAS:EYESW) » Definitions » EV-to-Revenue

EYESW (Second Sight Medical Products) EV-to-Revenue : (As of May. 29, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Second Sight Medical Products EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Second Sight Medical Products's enterprise value is $0.00 Mil. Second Sight Medical Products's Revenue for the trailing twelve months (TTM) ended in Jun. 2022 was $0.00 Mil. Therefore, Second Sight Medical Products's EV-to-Revenue for today is .

The historical rank and industry rank for Second Sight Medical Products's EV-to-Revenue or its related term are showing as below:

During the past 10 years, the highest EV-to-Revenue of Second Sight Medical Products was 702.13. The lowest was 4.85. And the median was 16.64.

EYESW's EV-to-Revenue is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 3.1
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-05-29), Second Sight Medical Products's stock price is $0.2198. Second Sight Medical Products's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 was $0.00. Therefore, Second Sight Medical Products's PS Ratio for today is .


Second Sight Medical Products EV-to-Revenue Historical Data

The historical data trend for Second Sight Medical Products's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Second Sight Medical Products EV-to-Revenue Chart

Second Sight Medical Products Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.84 9.15 24.90 - -

Second Sight Medical Products Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Second Sight Medical Products's EV-to-Revenue

For the Medical Devices subindustry, Second Sight Medical Products's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Second Sight Medical Products's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Second Sight Medical Products's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Second Sight Medical Products's EV-to-Revenue falls into.


;
;

Second Sight Medical Products EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Second Sight Medical Products's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=0.000/0
=

Second Sight Medical Products's current Enterprise Value is $0.00 Mil.
Second Sight Medical Products's Revenue for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Second Sight Medical Products  (NAS:EYESW) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Second Sight Medical Products's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.2198/
=

Second Sight Medical Products's share price for today is $0.2198.
Second Sight Medical Products's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Second Sight Medical Products EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Second Sight Medical Products's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Second Sight Medical Products Business Description

Traded in Other Exchanges
N/A
Address
13170 Telfair Avenue, Sylmar, CA, USA, 91342
Second Sight Medical Products Inc develops, manufactures, and markets implantable prosthetic devices to create an artificial form of useful vision for blind individuals. The company's product Argus II System treats outer retinal degenerations, such as Retinitis Pigmentosa, often referred to as RP. The company generates revenue from the sale of its Argus II retinal prosthesis systems, which include the implant and external components. Geographically, the company operates in the United States, Italy, China, and of which key revenue is derived from the United States.